Every material Form 8-K Contineum Therapeutics, Inc. has filed with the SEC since July 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Contineum Therapeutics reported third-quarter 2026 results on November 3, 2026. The net loss widened to $18.7 million from $12.8 million a year earlier, driven by higher research and development and general and administrative expenses. The company reported $244.5 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said this is sufficient to fund planned operations through mid-2029.
Net loss for the three months ended September 30, 2026 was $18.7 million, compared with $12.8 million in the third quarter of 2025.
Research and development expenses were $16.0 million, up 45 percent from a year earlier, mainly due to the PIPE-791 IPF program and employee-related costs.
General and administrative expenses were $5.0 million, up 26 percent, mainly due to higher stock-based compensation and employee-related costs.
Cash, cash equivalents and marketable securities were $244.5 million at September 30, 2026.
Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not achieve its primary efficacy endpoint. Johnson & Johnson, which develops the drug under a global license and development agreement, is still evaluating the data, including prespecified exploratory endpoints, to decide next steps.
Trial did not meet its primary efficacy endpoint, measured as change from baseline in MADRS total score at Day 5 versus placebo.
JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.
Johnson & Johnson continues to assess the totality and clinical relevance of the findings to inform next steps for the drug.
Analyses of the data, including prespecified exploratory endpoints, are ongoing.
Contineum Therapeutics reported second-quarter 2026 results on July 30, 2026, showing a net loss of $15.2 million, down from $16.0 million a year earlier. Research and development expenses fell 10 percent to $12.7 million, while general and administrative expenses rose 23 percent to $4.7 million. The company said it has a limited workforce reduction in research and its cash runway extends through mid-2029, which is relevant to shareholders because the company reported no revenue and relies on its cash balance to fund trials.
Net loss of $15.2 million, or $(0.40) per share, for the three months ended June 30, 2026, versus $16.0 million, or $(0.62) per share, a year earlier
Cash, cash equivalents and marketable securities of $236.6 million as of June 30, 2026, with cash runway projected through mid-2029
Limited workforce reduction in research, including Chief Scientific Officer Daniel Lorrain, as the company streamlines discovery programs
PROPEL-IPF Phase 2 trial of PIPE-791 has more than 55 sites online in eight countries
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Contineum Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →